Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Hausheer; Frederick H.
Address:
Boerne, TX
No. of patents:
46
Patents:












Patent Number Title Of Patent Date Issued
8143236 Chemoprotective methods March 27, 2012
Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents. In add
8026227 Chemoprotective methods and compositions September 27, 2011
Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.
7829541 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents November 9, 2010
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane
7829540 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents November 9, 2010
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane
7829539 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents November 9, 2010
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane
7829538 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents November 9, 2010
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane
7829117 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents November 9, 2010
Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane
7759488 Monoazole ligand platinum analogs July 20, 2010
Disclosed herein are novel platinum-based analogs with a single substituted azole ligand: RN.dbd.NR.sub.7, wherein the RN.dbd.NR.sub.7 functional group is covalently bonded to the platinum through nitrogen of NR.sub.7. The analogs also have nitrogen donor ligands capable of forming h
7687487 Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and us March 30, 2010
The present invention discloses: (i) a novel, lactone-stable, "flipped" E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, "flipped" E-ring camptothecin, pharmaceutically-acceptable salts, and/or an
7569606 Platinum complexes with mononitrile-containing ligands August 4, 2009
Disclosed herein are novel platinum-based complexes possessing one nitrile substituent group (mononitrile) covalently-bonded to the platinum, one or more nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA and leaving groups (i.e., L.sub.1 and L.sub.2 )w
7268244 Monoimine ligand platinum analogs September 11, 2007
Disclosed herein are novel platinum-based analogs with a single substituted imine ligand: R.sub.7RC.dbd.NR.sub.8, wherein the R.sub.7RC.dbd.NR.sub.8 functional group is covalently bonded to the platinum through nitrogen. The analogs also have nitrogen donor ligands capable of forming
7238823 Platinum complexes with mononitrile-containing ligands July 3, 2007
Disclosed herein are novel platinum-based complexes possessing one nitrile substituent group (mononitrile) covalently-bonded to the platinum, one or more nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA and leaving groups (i.e., L.sub.1 and L.sub.2) w
7176192 Method for treating patients for radiation exposure February 13, 2007
This invention relates to a method of treating a patient suffering from ionizing radiation exposure, or of treating a patient about to undergo ionizing radiation therapy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible d
6596320 Method for treating cancer having greater efficacy and reduced adverse effects July 22, 2003
A method of treating patients with cancer that involves administration of a combination regimen of a platinum agent, a taxane agent, and a formula I toxicity-reducing agent. The preferred order of administration is the formula I compound, followed by the platinum complex, followed by the
6525037 Method of treating atherosclerosis and complications resulting therefrom February 25, 2003
This invention relates to a method of treating patients afflicted with atherosclerosis or to prevent the development of atherosclerosis in patients assessed to be high risk of developing the disease. The method includes administering to a patient in need of treatment an effective amo
6468993 Method for reducing development of osteoporosis October 22, 2002
This invention relates to a method of treating patients afflicted with osteoporosis. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6468963 Methods and formulations for reducing toxicity associated with diabetes treatments October 22, 2002
Formulations and methods for reducing the unwanted toxicity and complications associated with treatments for diabetes mellitus. The formulations include co-formulations of an anti-diabetic agent and a toxicity reducing agent of the formula described in the specification. The methods
6291441 Method of treating inflammatory bowel disorders September 18, 2001
This invention relates to a method of treating patients suffering from the inflammatory bowel disorders. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specif
6274622 Method of treating diabetic ophthalmopathy August 14, 2001
This invention relates to a method of treating patients afflicted with diabetic ophthalmopathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6251881 Method of treating diabetic angiopathy June 26, 2001
This invention relates to a method of treating patients afflicted with diabetic angiopathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6225295 Method of treating acetaminophen overdose May 1, 2001
A method of treating patients suffering from acetaminophen overdose is disclosed. The method comprises administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6194579 Highly lipophilic camptothecin derivatives February 27, 2001
Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The f
6169080 Highly lipophilic camptothecin derivatives January 2, 2001
This invention relates to novel derivatives of camptothecin, and will, particularly to derivatives having a substitution at the C-7 position, or at one of the C-9, C-10, C-11 or C-12 positions, or to disubstituted derivatives having a first substitution at C-7 and a second at one of C-9,
6160167 Mercaptans and disulfides December 12, 2000
This invention relates to novel compositions of matter which either terminate in a sulfhydryl moiety or are disulfides. The compounds also include a terminal sulfonate or phosphonate moiety, and have many uses, such as toxicity reducing agents when administered with many antineoplast
6143796 Method for reducing development of free radical induced malignancies November 7, 2000
This invention relates to a method of treating patients at risk of developing a free radical induced malignancy. The method includes administering an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification to a patient at ri
6100247 Method of treating diabetic neuropathy August 8, 2000
This invention relates to a method of treating patients afflicted with diabetic neuropathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6066668 Formulations and methods of reducing toxicity of antineoplastic agents May 23, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6066645 Formulations and methods of reducing toxicity of antineoplastic agents May 23, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6057361 Formulations and methods of reducing toxicity of antineoplastic agents May 2, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6057303 Highly lipophilic Camptothecin derivatives May 2, 2000
Derivatives of Camptothecin are disclosed, particularly derivatives having multiple substitutions at the `A`, `B` and `E` rings thereof. The novel compounds are useful in treating a wide variety of susceptible tumors and are potent inhibitors of Topoisomerase I.
6048849 Formulations and methods of reducing toxicity of antineoplastic agents April 11, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6046234 Formulations and methods of reducing toxicity of antineoplastic agents April 4, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6046159 Formulations and methods of reducing toxicity of antineoplastic agents April 4, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6043274 Method of treating diabetic cardiomyopathy March 28, 2000
This invention relates to a method of treating patients afflicted with diabetic cardiomyopathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6043249 Formulations and methods of reducing toxicity of antineoplastic agents March 28, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6040312 Formulations and methods of reducing toxicity of antineoplastic agents March 21, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6040304 Formulations and methods of reducing toxicity of antineoplastic agents March 21, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6040294 Formulations and methods of reducing toxicity of antineoplastic agents March 21, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
6037336 Reducing toxic effects of carboplatin using dithioethers March 14, 2000
To reduce the toxic effect of carboplatin, particularly myelosuppression and emesis, a dithioether having the formula R.sub.1 -(CH.sub.2).sub.n --S--S--(CH.sub.2).sub.m --R.sub.2 (I) wherein:each of R.sub.1 and R.sub.2 individually is SO.sub.3 H or PO.sub.3 H.sub.2 ; andeach of m and n i
6031006 Method of treating diabetic nephropathy February 29, 2000
This invention relates to a method of treating patients afflicted with diabetic nephropathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
6028078 Highly lipophilic camptothecin derivatives February 22, 2000
Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The f
6025488 Formulations and methods of reducing toxicity of antineoplastic agents February 15, 2000
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
5935967 Pharmaceutical formulations of highly lipophilic camptothecin derivatives August 10, 1999
Pharmaceutical formulations of highly lipophilic, poorly water soluble derivatives of Camptothecin are disclosed. The formulations include an effective amount of the HLCD dissolved or suspended in an appropriate amount of N-methyl-2-pyrrolidinone (NMP), and one or more pharmaceutically
5922714 Combination of MDAM and 5-fluoropyrimidines for treating cancer July 13, 1999
A method of treating patients with cancer which includes administering to a patient in need of such treatment an effective amount of a combination of .gamma.-methylene-10-deazaaminopterin, and either a 5-fluoropyrimidine or S-1.
5919816 Formulations and methods of reducing toxicity of antineoplastic agents July 6, 1999
This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an
5910491 Highly lipophilic camptothecin derivatives June 8, 1999
Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The f










 
 
  Recently Added Patents
High performance adaptive switched LED driver
Method and apparatus for wireless communication in a mesh network with central control of communication relationships
Near-field optical disk having surface plasmon amplification by stimulated emission of radiation
Apparatus for restoring setting information of a board management controller from a backup memory before loading an OS when a system board is replaced
Information-provision control method, information reproduction system, information-provision apparatus, information reproduction apparatus and information-presentation control program
Low cost mesh network capability
(4937
  Randomly Featured Patents
Method of promoting enzyme diversity
System and method for molding soft fluid-filled implant shells
Low latency display methods for thin client devices
Method and structure of individually shielded, relay, pickup and holding coils, to reduce the effects of external and internal transients
Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same
Device for locking a pluggable electrical unit
Electric shifting device for a motor vehicle
Dispenser
Transmission system for the transmit part of a terminal associated with a digital mobile radio installation
Watch with watchstrap